Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
racepinephrine
- Development stage
- Phase 4
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
Racepinephrine is a racemic mixture of d-epinephrine and l-epinephrine enantiomers. It is a small molecule bronchodilator used for the temporary relief of mild symptoms of intermittent asthma such as wheezing, chest tightness, and shortness of breath. Racepinephrine acts as a non-selective agonist at alpha-adrenergic receptor and beta-adrenergic receptor (including α1, α2A, β1, and β2), leading to relaxation of airway smooth muscle (bronchodilation) and improved airflow. It is available over-the-counter in inhalation form for use with nebulizers or atomizers[1][2][3][4][5][8].
- Brand names
- AsthmanefrinS2S-2S 2S-2 InhalantS2 InhalantS 2 InhalantNephronMicronefrin
- Other names
- racepinephrine hydrochloride
02
Targets
ADRA1A (α1A)ADRB1 (β1)ADRA1 (Alpha-1 adrenergic receptor family)
Beyond the preview
Go deeper on racepinephrine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on racepinephrine.